CSF3 and Miyoshi myopathy: A US study comparing low-dose cyclophosphamide (1.5–2.0 g/kg/day) + G-CSF versus G-CSF + plerixafor in MM patients undergoing mobilization reported no significant difference in effectiveness with regard to collection of ≥2, ≥5, or ≥10 million CD34+ cells/kg [18].